# FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB Number: 3235-0287 Estimated average burden

hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

	Name and Address of Reporting Person <sup>*</sup>			2. Issuer Name <b>and</b> Ticker or Trading Symbol <u>SUTRO BIOPHARMA, INC.</u> [ STRO ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner						
(Last)		(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 05/01/2023		Officer (give title below)	Other (specify below)				
C/O SUTRO BIOPHARMA, INC.					p Officer						
111 OYSTER POINT BLVD.				4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line)						
(Street)	ANI					Form filed by One Report Form filed by More than	5				
FRANCISC		CA	94080	Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.							
(City)		(State)	(Zip)								

### Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

 2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transac Code (In 8)		4. Securities Ac Disposed Of (D		4 and 5)	Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership
		Code	v	Amount (A) or Price			Transaction(s) (Instr. 3 and 4)		(Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)		
Stock Option (right to buy Common Stock)	\$4.58	05/01/2023		А		7,500		(1)	05/01/2033	Common Stock	7,500	\$0.00	7,500	D	
Restricted Stock Unit (RSU)	(2)	05/01/2023		Α		10,000		(3)	05/01/2027	Common	10,000	\$0.00	10,000	D	

#### Explanation of Responses:

1. The option vests as to 2.0833% of the total shares monthly, beginning on June 1, 2023, with 100% of the total shares vested and exercisable on May 1, 2027, subject to the reporting person's provision of service to the issuer on each vesting date.

2. Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement.

3. The RSUs vest as to 1/4th of the total shares annually beginning on May 1, 2024, subject to continued service through each vesting date.

### Remarks:

/s/ Edward C. Albini as attorney-05/02/2023 in-fact for Venkatesh Srinivasan

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

OMB APPROVAL